COMMUNIQUÉS West-GlobeNewswire

Oncotelic Announces Peer-Reviewed Validation of Deciparticle™ Platform Supporting Clinical Development of Sapu003
29/06/2026
Publication Highlights Novel Intravenous Everolimus Formulation and Demonstrates Broad Potential of Deciparticle ™ Technology for Hydrophobic Therapeutics SAN DIEGO, Calif., June 29, 2026 (GLOBE NEWSWIRE) -- Oncotelic [...]
Palisade Bio Receives FDA Clearance of IND for PALI-2108 and Plans to Initiate Global Phase 2 ASCENTRA-UC Study in Ulcerative Colitis
29/06/2026
ASCENTRA-UC expected to enroll up to 204 patients with moderately to severely active ulcerative colitis across North America and Europe First patient enrollment anticipated in the second half of 2026; primary efficacy [...]
TOMI Environmental Solutions Announces Definitive Agreement to Merge with Carbonium Core
29/06/2026
Transaction will create a public market pure-play on America's nuclear renaissance, positioned at the intersection of AI-driven power demand, advanced nuclear reactors, and domestic critical materials production [...]
Approval from Health Canada to expand Serenta Registrational Phase 3 trial in FAP and Update on Serenta Progress
29/06/2026
June 29, 2026 Approval from Health Canada to expand Serenta Registrational Phase 3 trial in FAP and Update on Serenta Progress Biodexa Pharmaceuticals PLC (Nasdaq: BDRX) (“Biodexa” or “the Company”), a clinical stage [...]
Novo Nordisk A/S - share repurchase programme
29/06/2026
Bagsværd, Denmark, 29 June 2026 – On 6 May 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) [...]
VivoSim Presents Data Showing Superiority to Competition in NAM Liver Tox Prediction at European Toxicology Meeting
29/06/2026
VivoSim Demonstrates Leadership in Field through AI-enabled NAMkind™ Liver and Intestine with High Accuracy Results, Including for Antibody Drug Conjugates (ADCs) SAN DIEGO, June 29, 2026 (GLOBE NEWSWIRE) -- VivoSim [...]
Voyager’s Tau-Targeted Gene Therapy VY1706 for Alzheimer’s Disease to Be Featured in Developing Topics Poster Presentation at AAIC 2026
29/06/2026
LEXINGTON, Mass., June 29, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced a Developing Topics [...]
Rani Therapeutics Appoints Nicholas Maestas as Chief Financial Officer
29/06/2026
SAN JOSE, Calif., June 29, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics”; “Rani” or the “Company”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery [...]
4DMT Completes Enrollment for 4FRONT-2 Global Phase 3 Clinical Trial of 4D-150 in Wet AMD
29/06/2026
4FRONT-2 global enrollment completed approximately 4 months ahead of initial projections 4FRONT-2 over-enrolled (anticipated N>500), with final patient randomization expected in Q3 2026, reflecting strong interest [...]
IMDx Chief Science Officer Ekkehard Schuetz Publishes 200th Research Paper
29/06/2026
Key member of management ranks at top 2% of researchers in the field of laboratory diagnostics and top 2.5% of all researchers worldwide, based on H-index of 58 Recent studies advanced science of molecular diagnostic [...]
HealthLynked Launches AI-Powered Healthcare Communication Platform Featuring 24/7 Appointment Scheduling and Medical Office AI Agents
29/06/2026
NAPLES, Fla., June 29, 2026 (GLOBE NEWSWIRE) -- via IBN – HealthLynked Corp. (OTCQB: HLYK ), a leader in healthcare technology, patient engagement, and care coordination, today announced the launch of its next- [...]
Replimune Reports Fiscal Fourth Quarter and Year End 2026 Financial Results and Provides Corporate Update
29/06/2026
WOBURN, Mass., June 29, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced financial [...]
Mdxhealth Announces Peer-Reviewed Publication of Oxford GPS-ProMPT Study in European Urology Oncology, Establishing Scientific Foundation for the Landmark GPS-ProtecT Randomized Controlled Trial
29/06/2026
Mdxhealth Announces Peer-Reviewed Publication of Oxford GPS-ProMPT Study in European Urology Oncology, Establishing Scientific Foundation for the Landmark GPS-ProtecT Randomized Controlled Trial IRVINE, California – [...]
Dyadic Expands IP Protection and Business Development Activities in Japan
29/06/2026
Bolsters Japan Market Expansion, Strategic Collaborations and Demand for Scalable Recombinant Protein Solutions JUPITER, Fla., June 29, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (Nasdaq: DYAI) (“Dyadic” or the [...]
Zelluna ASA: Mandatory notification of trade – Return of lent shares following Private Placement
29/06/2026
Oslo, 29 June 2026 : Reference is made to the stock exchange announcement by Zelluna ASA (the "Company") on 18 June 2026 regarding completion of a private placement of 3,143,958 new shares at a subscription price of NOK [...]
George Medicines appoints Brendan Walsh as Senior Vice President of Supply Chain & Technical Operations
29/06/2026
Brendan Walsh brings more than 20 years of operational leadership to support George Medicines’ global commercial expansion of GMRx2 London, UK, Boston, MA, 29 June 2026 – George Medicines, a late-stage biopharmaceutical [...]
Relmada Therapeutics Joins Russell 2000® and Russell 3000® Indexes
29/06/2026
CORAL GABLES, Fla., June 29, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central [...]
Sagimet Biosciences Joins the Russell 2000® and Russell 3000® Indexes
29/06/2026
SAN MATEO, Calif., June 29, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic [...]
Agios to Host Second Quarter 2026 Financial Results Conference Call and Webcast on July 30 at 8:00 a.m. ET
29/06/2026
CAMBRIDGE, Mass., June 29, 2026 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, [...]

Pages